ReviewDrugs in context2022
Diabetes: how to manage diabetic peripheral neuropathy.
Review in Drugs in context, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 4 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Evaluating the Effects of Nanocurcumin Supplementation in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Endocrinology, diabetes & metabolism · 2026Pooled it
- Exercise training and balance function in middle-aged and older adults with diabetic peripheral neuropathy: a GRADE-based systematic review and meta-analysis.Frontiers in public health · 2026Pooled it
- Machine learning in the prediction of diabetic peripheral neuropathy: a systematic review.BMC medical informatics and decision making · 2025Pooled it
- The Landscape of Products for Diabetic Peripheral Neuropathy: A Scientific and Patent Systematic Review.Recent patents on biotechnology · 2025Pooled it
- Efficacy and Safety of Pregabalin and Alpha-Lipoic Acid Combination in Patients With Painful Diabetic Peripheral Neuropathy: A Randomized, Open-Label, Non-Inferiority, Phase IV Clinical Trial and Subgroup Analysis (OPTIMUM Study).Diabetes, obesity & metabolism · 2026Trial
- The effectiveness and safety of nanocurcumin supplementation for diabetic peripheral neuropathy in patients with type 2 diabetes: a randomized double-blind clinical trial.Nutrition journal · 2025Trial
- Consensus on the Clinical Use of Pregabalin in Peripheral Neuropathic Pain.CNS neuroscience & therapeutics · 2026Review
- Advanced age and elevated cholesterol predict diabetic neuropathy in patients with type II diabetes mellitus in Southern Ethiopia.Cardiovascular diabetology. Endocrinology reports · 2025Article
- Impact of HbA1c variability and time-in-range fluctuations on large and small nerve fiber dysfunction in well-controlled type 2 diabetes: A prospective cohort observational study.Journal of diabetes investigation · 2025Observational
- The combination of neurotropic B vitamins (B1, B6, and B12) is superior to individual B vitamins in promoting neurite growth in vitro.In vitro cellular & developmental biology. Animal · 2025Article
- Pyroptosis in Diabetic Peripheral Neuropathy and its Therapeutic Regulation.Journal of inflammation research · 2024Review
- Antioxidant Phytochemicals as Potential Therapy for Diabetic Complications.Antioxidants (Basel, Switzerland) · 2023Review
- Novel Cinnamaldehyde Derivatives Inhibit Peripheral Nerve Degeneration by Targeting Schwann Cells.Antioxidants (Basel, Switzerland) · 2022Article
- Bacterial profile and antimicrobial resistance patterns of infected diabetic foot ulcers in low- and middle-income countries: a systematic review and meta‑analysis.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic peripheral neuropathy (DPN) is a major complication of diabetes mellitus. Tight glycaemic management focused on lowering haemoglobin A1C and increasing time in the target glucose range along with metabolic risk factor management form the cornerstone of DPN prevention. However, there is limited evidence supporting the efficacy of glycaemic and metabolic control in reducing the symptoms and complications of DPN, including pain once painful DPN develops. DPN treatments include pharmacological agents and non-pharmacological interventions such as foot care and lifestyle modifications. Pharmacological agents primarily address pain symptoms, which affect 25-35% of people with DPN. First-line agents include the anticonvulsants pregabalin and gabapentin, the serotonin-norepinephrine reuptake inhibitors duloxetine and venlafaxine, and secondary amine tricyclic antidepressants, including nortriptyline and desipramine. All agents have unique pharmacological, safety and clinical profiles, and agent selection should be guided by the presence of comorbidities, potential for adverse effects, drug interactions and costs. Even with the current treatment options, people are commonly prescribed less than the recommended dose of medications, leading to poor management of DPN symptoms and treatment discontinuation. By keeping up with the latest therapy algorithms and treatment options, healthcare professionals can improve the care for people with DPN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.